Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 3/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633996 | 1.00 | CYP1A1 (0.64) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL1881107 | 0.89 | CYP1A1 (0.64) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL30736480 | 0.89 | CYP1A1 (0.72) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL31436378 | 0.89 | CYP1A1 (0.72) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL17988080 | 0.89 | CYP1B1 (0.67) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL14315253 | 0.89 | CYP1A1 (0.72) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL1882355 | 0.89 | CYP1A1 (0.72) | CYP1A1CYP1B1CYP1A2MAPTNPC1 | |
| SCHEMBL19182775 | 0.88 | ABCG2 (0.67) | MAPTMEN1KMT2ATNFRSF1ATDP1 | |
| SCHEMBL19182774 | 0.88 | ABCG2 (0.67) | MAPTMEN1KMT2ATNFRSF1ATDP1 | |
| SCHEMBL21647189 | 0.86 | MCL1 (0.60) | MAPTMEN1KMT2ATDP1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CYP1A1 215/4885CYP1B1 316/4885CYP1A2 319/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | CYP1A1 4202/4885CYP1B1 3535/4885CYP1A2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.